Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 mai 2018 17h00 HE | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Publication of REOLYSIN® Abstract for the ASCO 2018 Annual Meeting

CALGARY, Alberta and SAN DIEGO, May 16, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
11 mai 2018 07h00 HE | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Reports 2018 First Quarter Results

CALGARY, Alberta and SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
10 mai 2018 07h00 HE | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer

CALGARY, Alberta and SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
04 mai 2018 16h00 HE | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Voting Results from its Annual General Meeting of Shareholders

CALGARY, Alberta and SAN DIEGO, May 04, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered...